THERAPEUTIC EFFECTS OF A NOVEL FUSION OF ALT-803, AN IL-15 SUPERAGONIST, WITH 4 SINGLE-CHAINS OF ANTI-CD20 ANTIBODY (2B8T2M) IN COMBINATION WITH EXPANDED NATURAL KILLER CELLS AGAINST RITUXIMAB SENSITIVE AND RESISTANT BURKITT LYMPHOMA (BL)

Chu Y.; Su N.; Alter S.; Jeng E.; Rhode P.; Barth M.; Lee D.; Wong H. C.; Cairo M. S.

首页> 外文期刊>Cytotherapy >THERAPEUTIC EFFECTS OF A NOVEL FUSION OF ALT-803, AN IL-15 SUPERAGONIST, WITH 4 SINGLE-CHAINS OF ANTI-CD20 ANTIBODY (2B8T2M) IN COMBINATION WITH EXPANDED NATURAL KILLER CELLS AGAINST RITUXIMAB SENSITIVE AND RESISTANT BURKITT LYMPHOMA (BL)

【24h】

THERAPEUTIC EFFECTS OF A NOVEL FUSION OF ALT-803, AN IL-15 SUPERAGONIST, WITH 4 SINGLE-CHAINS OF ANTI-CD20 ANTIBODY (2B8T2M) IN COMBINATION WITH EXPANDED NATURAL KILLER CELLS AGAINST RITUXIMAB SENSITIVE AND RESISTANT BURKITT LYMPHOMA (BL)

机译：Alt-803的新融合的治疗效应，IL-15超大胶质剂，4个单链的抗CD20抗体（2b8t2m）与针对拉妥昔单抗敏感和抗性Burkitt淋巴瘤（BL）的膨胀自然杀伤细胞组合

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Cytotherapy》 |2018年第5suppla期|共1页
作者
Chu Y.; Su N.; Alter S.; Jeng E.; Rhode P.; Barth M.; Lee D.; Wong H. C.; Cairo M. S.;
展开▼
作者单位

New York Med Coll Pediat Valhalla NY 10595 USA;

New York Med Coll Pediat Valhalla NY 10595 USA;

Altor BioSci Miramar FL USA;

Altor BioSci Miramar FL USA;

Altor BioSci Miramar FL USA;

SUNY Buffalo Pediat Buffalo NY USA;

Nationwide Childrens Hosp Hem Onc BMT Columbus OH USA;

Altor BioSci Miramar FL USA;

New York Med Coll Pediat Valhalla NY 10595 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类细胞工程;
关键词

相似文献

外文文献
专利

1. THERAPEUTIC EFFECTS OF A NOVEL FUSION OF ALT-803, AN IL-15 SUPERAGONIST, WITH 4 SINGLE-CHAINS of ANTI-CD20 ANTIBODY (2B8T2M) IN COMBINATION WITH EXPANDED NATURAL KILLER CELLS AGAINST RITUXIMAB SENSITIVE AND RESISTANT BURKITT LYMPHOMA (BL) [J] . Chu Yaya, Su Nang Kham, Alter Sarah, Pediatric blood & cancer . 2018,第Suppla1期

机译：ALT-803，IL-15超大抗体的新融合的治疗效果与抗CD20抗体（2b8t2m）的4个单链相结合，与Rituximab敏感和抗性Burkitt淋巴瘤（BL）组合的膨胀性天然杀伤细胞
2. Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL) [J] . Yaya Chu, Nang Kham Su, Sarah Alter, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第3期

机译：ALT-803，IL-15超大抗体的新融合的治疗效果与抗CD20抗体（2b8t2m）的4个单链相结合，与Rituximab敏感和抗性Burkitt淋巴瘤（BL）组合的膨胀性天然杀伤细胞
3. Therapeutic Effects of a Novel Fusion of ALT-803, an IL-15 Superagonist, with 4 Single-Chains of Anti-CD20 Antibody (2B8T2M) in Combination with Expanded Natural Killer Cells Against Rituximab Sensitive and Resistant Burkitt Lymphoma (BL) [J] . Yaya Chu, Nang Kham Su, Sarah Alter, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2018,第3期

机译：ALT-803，IL-15超大抗体的新融合的治疗效果与抗CD20抗体（2b8t2m）的4个单链相结合，与Rituximab敏感和抗性Burkitt淋巴瘤（BL）组合的膨胀性天然杀伤细胞
4. The IL-15 superagonist ALT-803 enhances anti-CD20 antibody-directed NK cell ADCC and in vivo clearance of B cell lymphomas [O] . Maximillian Rosario, Bai Liu, Lin Kong, 2014

机译：IL-15超激动剂ALT-803增强抗CD20抗体指导的NK细胞ADCC和B细胞淋巴瘤的体内清除率
5. Anti-CD20 Chimeric Antigen Receptor (CAR) Modified Expanded Natural Killer (NK) Cells Significantly Mediate Rituximab Sensitive and Resistant Burkitt Lymphoma (BL) Regression and Improve Survival in Human BL Xenografted NSG Mice [O] . Chu Yaya, Yahr Ashlin, Ayello Janet, 2014

机译：抗CD20嵌合抗原受体（CAR）修饰的扩展的自然杀手（NK）细胞显着介导利妥昔单抗敏感和抵抗性伯基特淋巴瘤（BL）回归，并提高了人类BL异种移植NSG小鼠的存活率。

THERAPEUTIC EFFECTS OF A NOVEL FUSION OF ALT-803, AN IL-15 SUPERAGONIST, WITH 4 SINGLE-CHAINS OF ANTI-CD20 ANTIBODY (2B8T2M) IN COMBINATION WITH EXPANDED NATURAL KILLER CELLS AGAINST RITUXIMAB SENSITIVE AND RESISTANT BURKITT LYMPHOMA (BL)

著录项

相似文献

相关主题

期刊订阅